Lucius LuciTivo Tivozanib 1.34mg

Product Information

• Product name: LuciTivo Tivozanib 1.34mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Tivozanib
• Current strength: 1.34mg
• SKU: LU-ITEM-119
• Site category: kidney cancer, other cancer

Product Summary

LuciTivo Tivozanib 1.34mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Tivozanib is the active ingredient used for this product page. Public prescribing information for Tivozanib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Tivozanib is a tyrosine kinase inhibitor.

Reference Indications

Tivozanib is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Tivozanib is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Reference Dosage and Administration

The public label should be checked for the indication-specific recommended dosage. Available administration instructions note that the medicine may be taken Recommended Dose: 1. with or without food for 21 days on treatment followed by 7 days off treatment (28-day cycle) until disease progression or unacceptable toxicity.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Hypertension and Hypertensive Crisis: Control blood pressure prior to initiating Tivozanib. Monitor for hypertension and treat as needed. Cardiac Failure: Monitor for signs or symptoms of cardiac failure throughout treatment with Tivozanib. Cardiac Ischemia and Arterial Thromboembolic Events: Closely monitor patients who are at increased risk for these events. Permanently discontinue Tivozanib for severe arterial thromboembolic events, such as myocardial infarction and stroke. Venous Thromboembolic Events: Closely monitor patients who are at increased risk for these events. Permanently discontinue Tivozanib for severe venous thromboembolic events. Hemorrhagic Events: Closely monitor patients who are at risk for or who have a history of bleeding. Proteinuria: Monitor throughout treatment with Tivozanib.

Common Adverse Reactions and Monitoring

The pooled safety population described in reflects exposure to Tivozanib administered at 1.34 mg orally once daily with or without food for 21 days on treatment followed by 7 days off treatment for a 28-day cycle in 1008 patients with advanced RCC in TIVO-3 and five other monotherapy studies. Among 1008 patients who received Tivozanib, 52% were exposed for 6 months or longer and 34% were exposed for greater than one year. Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies The safety of Tivozanib was evaluated in TIVO-3, a randomized, open-label trial in 350 patients with relapsed or refractory advanced RCC who received 2 or 3 prior systemic treatments .

Drug Interactions and Special Populations

CYP3A Inducers: Avoid concomitant use of strong CYP3A inducers. Avoid concomitant use of strong CYP3A inducers with Tivozanib. Lactation: Advise not to breastfeed. Females and Males of Reproductive Potential: Can impair fertility. Hepatic Impairment: Adjust dosage in patients with moderate hepatic impairment. Avoid use in patients with severe hepatic impairment. ( 2.3 , 8.7 ) 8.1 Pregnancy Risk Summary Based on findings in animal studies and its mechanism of action, Tivozanib can cause fetal harm when administered to a pregnant woman . There are no available data on Tivozanib use in pregnant woman to inform the drug-associated risk. Advise pregnant woman of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: FOTIVDA public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.